Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 4/20 | 0.52 |
| ▸ | ESR2 known ✓ | Q92731 | 4/20 | 0.52 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.41 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1823 | 0.97 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL4055738 | 0.97 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL5598857 | 0.97 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL211632 | 0.97 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL30067172 | 0.94 | CYP3A4 (0.71) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL29359632 | 0.94 | CYP3A4 (0.71) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL2653270 | 0.94 | CYP3A4 (0.71) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL6415873 | 0.94 | CYP3A4 (0.71) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL30041418 | 0.94 | CYP3A4 (0.71) | CYP3A4TDP1ESR1ESR2KDM4E | |
| Methane SCHEMBL28585682 | 0.94 | CYP3A4 (0.71) | CYP3A4TDP1ESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027636-B1 | D-AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF HALOGENO PYRIMIDINE COMPOUNDS FOR LIVER DISEASE | IDENIX PHARMACEUTICALS LLC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10238680-B2 | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease | IDENIX PHARMACEUTICALS LLC (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3027636-A1 | D-AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF HALOGENO PYRIMIDINE COMPOUNDS FOR LIVER DISEASE | Idenix Pharmaceuticals LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20160082030-A1 | D-AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF HALOGENO PYRIMIDINE COMPOUNDS FOR LIVER DISEASE | UNIVERSITE DE MONTPELLIER (FR) | 2016-03-24 | — | — | US | disclosed |
| US-20150037282-A1 | D-AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF HALOGENO PYRIMIDINE COMPOUNDS FOR LIVER DISEASE | IDENIX PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| WO-2015017713-A1 | D-AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF HALOGENO PYRIMIDINE COMPOUNDS FOR LIVER DISEASE | IDENIX PHARMACEUTICALS, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-6593480-B2 | Obesity, hyperglycemia | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| WO-2002070507-A2 | GLYCORTICOID RECEPTOR ANTAGONISTS FOR TREATMENT OF DIABETES | ABBOTT LABORATORIES (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1159275-A2 | IMIDAZOLE COMPOUNDS AS HISTAMINE H3 LIGANDS | SCHERING CORPORATION (US) | 2001-12-05 | — | — | EP | disclosed |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | KARO BIO AB (SE) | 2001-11-15 | — | — | US | disclosed |
| US-6211182-B1 | HISTAMINE H3-ANTAGONISTS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS, ANTIASTHMATICS; NERVOUS SYSTEM, PSYCHOLOGICAL, SLEEP, AND GASTROINTESTINAL DISORDERS | SCHERING CORPORATION | 2001-04-03 | — | — | US | disclosed |
| WO-2000053596-A2 | IMIDAZOLE COMPOUNDS AS HISTAMINE H3 LIGANDS | SCHERING CORPORATION (US) | 2000-09-14 | — | — | WO | disclosed |
| US-6069151-A | Quinolines and their therapeutic use | DARWIN DISCOVERY, LTD. (GB) | 2000-05-30 | — | — | US | disclosed |
| EP-0993449-A1 | QUINOLINE DERIVATIVES AS PDE IV AND/OR TNF INHIBITORS | Darwin Discovery Limited (GB) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998057936-A1 | QUINOLINE DERIVATIVES AS PDE IV AND/OR TNF INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 1998-12-23 | — | — | WO | disclosed |
| EP-0623120-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014077-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150037282-A1 | D-AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF HALOGENO PYRIMIDINE COMPOUNDS FOR LIVER DISEASE | PNP, ATIC, SLC29A1 | ESR1 2803/4885ESR2 2798/4885GAA 1720/4885 |
| US-20160082030-A1 | D-AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF HALOGENO PYRIMIDINE COMPOUNDS FOR LIVER DISEASE | PNP, ATIC, SLC29A1 | ESR1 2803/4885ESR2 2798/4885GAA 1720/4885 |
| US-20010041802-A1 | Glucocorticoid receptor antagonists for treatment of diabetes | NR3C1, GPR119, NR3C2 | ESR1 780/4885ESR2 269/4885GAA 1444/4885 |
| US-10238680-B2 | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease | PNP, ATIC, SLC29A1 | ESR1 2803/4885ESR2 2798/4885GAA 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.